In breast and colon cancers, high expression of TREX1 leads to blockage of type I IFN pathway activation, inhibiting the anti-tumor immune response and the anti-tumor response of immune checkpoint inhibitors (61, 62). This evidence concerns the gene TREX1 and colonic neoplasm.